231 related articles for article (PubMed ID: 25840602)
1. Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.
Agathanggelou A; Weston VJ; Perry T; Davies NJ; Skowronska A; Payne DT; Fossey JS; Oldreive CE; Wei W; Pratt G; Parry H; Oscier D; Coles SJ; Hole PS; Darley RL; McMahon M; Hayes JD; Moss P; Stewart GS; Taylor AM; Stankovic T
Haematologica; 2015 Aug; 100(8):1076-85. PubMed ID: 25840602
[TBL] [Abstract][Full Text] [Related]
2. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
[TBL] [Abstract][Full Text] [Related]
3. NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines.
Verner J; Trbusek M; Chovancova J; Jaskova Z; Moulis M; Folber F; Halouzka R; Mayer J; Pospisilova S; Doubek M
Leuk Lymphoma; 2015; 56(11):3198-206. PubMed ID: 25827173
[TBL] [Abstract][Full Text] [Related]
4. The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
Navrkalova V; Sebejova L; Zemanova J; Jaskova Z; Trbusek M
Leuk Lymphoma; 2013 Aug; 54(8):1840-3. PubMed ID: 23808769
[TBL] [Abstract][Full Text] [Related]
5. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
6. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
7. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
Agathanggelou A; Smith E; Davies NJ; Kwok M; Zlatanou A; Oldreive CE; Mao J; Da Costa D; Yadollahi S; Perry T; Kearns P; Skowronska A; Yates E; Parry H; Hillmen P; Reverdy C; Delansorne R; Paneesha S; Pratt G; Moss P; Taylor AMR; Stewart GS; Stankovic T
Blood; 2017 Jul; 130(2):156-166. PubMed ID: 28495793
[TBL] [Abstract][Full Text] [Related]
8. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.
Navrkalova V; Sebejova L; Zemanova J; Kminkova J; Kubesova B; Malcikova J; Mraz M; Smardova J; Pavlova S; Doubek M; Brychtova Y; Potesil D; Nemethova V; Mayer J; Pospisilova S; Trbusek M
Haematologica; 2013 Jul; 98(7):1124-31. PubMed ID: 23585524
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone improves redox state in ataxia telangiectasia cells by promoting an NRF2-mediated antioxidant response.
Biagiotti S; Menotta M; Orazi S; Spapperi C; Brundu S; Fraternale A; Bianchi M; Rossi L; Chessa L; Magnani M
FEBS J; 2016 Nov; 283(21):3962-3978. PubMed ID: 27636396
[TBL] [Abstract][Full Text] [Related]
10. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM; Zenz T; Skowronska A; Hoogendoorn M; Stankovic T; van Oers MH; Eldering E; Kater AP
Cell Death Dis; 2015 Aug; 6(8):e1852. PubMed ID: 26247737
[TBL] [Abstract][Full Text] [Related]
11. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
[TBL] [Abstract][Full Text] [Related]
12. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.
Stankovic T; Skowronska A
Leuk Lymphoma; 2014 Jun; 55(6):1227-39. PubMed ID: 23906020
[TBL] [Abstract][Full Text] [Related]
13. Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.
te Raa GD; Malcikova J; Pospisilova S; Trbusek M; Mraz M; Garff-Tavernier ML; Merle-Béral H; Lin K; Pettitt AR; Merkel O; Stankovic T; van Oers MH; Eldering E; Stilgenbauer S; Zenz T; Kater AP;
Leuk Lymphoma; 2013 Aug; 54(8):1849-53. PubMed ID: 23614766
[TBL] [Abstract][Full Text] [Related]
14. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
[TBL] [Abstract][Full Text] [Related]
15. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
16. PRIMA-1
Jaskova Z; Pavlova S; Malcikova J; Brychtova Y; Trbusek M
Leuk Res; 2020 Feb; 89():106288. PubMed ID: 31924585
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
[TBL] [Abstract][Full Text] [Related]
18. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
[TBL] [Abstract][Full Text] [Related]
19. Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
Lozano-Santos C; García-Vela JA; Pérez-Sanz N; Nova-Gurumeta S; Fernandez-Cuevas B; Gomez-Lozano N; Sánchez-Beato M; Sanchez-Godoy P; Bueno JL; Garcia-Marco JA
Leuk Lymphoma; 2017 Apr; 58(4):859-865. PubMed ID: 27499002
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]